Kraef Christian, Lillebæk Troels, Andersen Åse Bengård, Kirk Ole
Afdeling for Infektionssygdomme, Hjertecentret, Københavns Universitetshospital - Rigshospitalet.
Tuberkulose og Mykobakterier, Statens Serum Institut.
Ugeskr Laeger. 2022 Mar 7;184(10).
Tuberculosis (TB) is still a major challenge for global health, but in recent years there have been several important developments in treatment options. Shorter treatment regimens for latent TB, based on conventional drugs, offer better adherence and fewer side effects, while new and repurposed antibiotics have opened the door to more effective, shorter and less side effect-heavy treatments for drug susceptible TB and multidrug-resistant/extensively drug resistant TB as well as atypical mycobacterioses. This review investigates how these shorter and predominantly oral treatments, in the future, are expected to be used in combination with individualized precision medicine.
结核病（TB）仍然是全球卫生领域的一项重大挑战，但近年来治疗方案有了几项重要进展。基于传统药物的潜伏性结核病短程治疗方案具有更好的依从性和更少的副作用，而新型和重新利用的抗生素为药物敏感型结核病、耐多药/广泛耐药结核病以及非结核分枝杆菌病带来了更有效、更短且副作用更少的治疗方法。本综述探讨了这些未来的短程且主要为口服的治疗方法预计将如何与个体化精准医学相结合使用。
